Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

被引：4

作者：

Barca, Eva Gonzalez ^{[1
]}

机构：

[1] Univ Barcelona, Catalan Inst Oncol, Hematol Dept, IDIBELL, Barcelona 08908, Spain

来源：

JOURNAL OF CLINICAL MEDICINE | 2023年 / 12卷 / 23期

关键词：

diffuse large B-cell lymphoma; relapsed/refractory; therapy; efficacy; toxicity; SINGLE-ARM; BRENTUXIMAB VEDOTIN; OPEN-LABEL; PHASE-III; R-CHOP; RITUXIMAB; LENALIDOMIDE; MULTICENTER; PREDNISONE; IBRUTINIB;

D O I：

10.3390/jcm12237376

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and biologically heterogeneous disease. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first-line chemo immunotherapy. In recent years, there have been several new therapeutic agents approved for the treatment of relapsed/refractory (R/R) DLBCL. These agents include anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) and monoclonal antibody therapies such as polatuzumab and tafasitamab. Nevertheless, despite the high efficacy of all these new therapies, there are still patients who do not respond or relapse, representing an unmet clinical need. This review describes new promising therapies that are in clinical development to treat R/R DLBCL.

引用

页数：12

共 50 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Abramson, Jeremy S.
Palomba, M. Lia
Gordon, Leo I.
Lunning, Matthew A.
Wang, Michael
Arnason, Jon
Mehta, Amitkumar
Purev, Enkhtsetseg
Maloney, David G.
Andreadis, Charalambos
Sehgal, Alison
Solomon, Scott R.
Ghosh, Nilanjan
Albertson, Tina M.
Garcia, Jacob
Kostic, Ana
Mallaney, Mary
Ogasawara, Ken
Newhall, Kathryn
Kim, Yeonhee
Li, Daniel
Siddiqi, Tanya
[J]. LANCET, 2020, 396 (10254) : 839 - 852
[2] CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Advani, Ranjana
Flinn, Ian
Popplewell, Leslie
Forero, Andres
Bartlett, Nancy L.
Ghosh, Nilanjan
Kline, Justin
Roschewski, Mark
LaCasce, Ann
Collins, Graham P.
Thu Tran
Lynn, Judith
Chen, James Y.
Volkmer, Jens-Peter
Agoram, Balaji
Huang, Jie
Majeti, Ravindra
Weissman, Irving L.
Takimoto, Chris H.
Chao, Mark P.
Smith, Sonali M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (18) : 1711 - 1721
[3] Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
Bannerji, Rajat
Arnason, Jon E.
Advani, Ranjana H.
Brown, Jennifer R.
Allan, John N.
Ansell, Stephen M.
Barnes, Jeffrey A.
O'Brien, Susan M.
Chavez, Julio C.
Duell, Johannes
Rosenwald, Andreas
Crombie, Jennifer L.
Ufkin, Melanie
Li, Jingjin
Zhu, Min
Ambati, Srikanth R.
Chaudhry, Aafia
Lowy, Israel
Topp, Max S.
[J]. LANCET HAEMATOLOGY, 2022, 9 (05): : E327 - E339
[4] Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
Bishop, M. R.
Dickinson, M.
Purtill, D.
Barba, P.
Santoro, A.
Hamad, N.
Kato, K.
Sureda, A.
Greil, R.
Thieblemont, C.
Morschhauser, F.
Janz, M.
Flinn, I
Rabitsch, W.
Kwong, Y-L
Kersten, M. J.
Minnema, M. C.
Holte, H.
Chan, E. H. L.
Martinez-Lopez, J.
Mueller, A. M. S.
Maziarz, R. T.
McGuirk, J. P.
Bachy, E.
Le Gouill, S.
Dreyling, M.
Harigae, H.
Bond, D.
Andreadis, C.
McSweeney, P.
Kharfan-Dabaja, M.
Newsome, S.
Degtyarev, E.
Awasthi, R.
del Corral, C.
Andreola, G.
Masood, A.
Schuster, S. J.
Jaeger, U.
Borchmann, P.
Westin, J. R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07) : 629 - 639
[5] The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy
Caimi, Paolo F.
Ardeshna, Kirit M.
Reid, Erin
Ai, Weiyun
Lunning, Matthew
Zain, Jasmine
Solh, Melhem
Kahl, Brad S.
Hamadani, Mehdi
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05) : E335 - E339
[6] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Caimi, Paolo F.
Ai, Weiyun
Alderuccio, Juan Pablo
Ardeshna, Kirit M.
Hamadani, Mehdi
Hess, Brian
Kahl, Brad S.
Radford, John
Solh, Melhem
Stathis, Anastasios
Zinzani, Pier Luigi
Havenith, Karin
Feingold, Jay
He, Shui
Qin, Yajuan
Ungar, David
Zhang, Xiaoyan
Carlo-Stella, Carmelo
[J]. LANCET ONCOLOGY, 2021, 22 (06) : 790 - 800
[7] Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Chong, Elise A.
Svoboda, Jakub
Nasta, Sunita Dwivedy
Landsburg, Daniel J.
Winchell, Nicole
Napier, Ellen
Mato, Anthony R.
Melenhorst, J. Joseph
Ruella, Marco
Lacey, Simon F.
June, Carl H.
Schuster, Stephen J.
[J]. BLOOD, 2018, 132
[8] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier, B
Lepage, E
Brière, J
Herbrecht, R
Tilly, H
Bouabdallah, R
Morel, P
Van den Neste, E
Salles, G
Gaulard, P
Reyes, F
Gisselbrecht, C
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
[9] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, Michael
Neelapu, Sattva S.
Farooq, Umar
Van den Neste, Eric
Kuruvilla, John
Westin, Jason
Link, Brian K.
Hay, Annette
Cerhan, James R.
Zhu, Liting
Boussetta, Sami
Feng, Lei
Maurer, Matthew J.
Navale, Lynn
Wiezorek, Jeff
Go, William Y.
Gisselbrecht, Christian
[J]. BLOOD, 2017, 130 (16) : 1800 - 1808
[10] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Dickinson, Michael J.
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Tomasz
Offner, Fritz
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Sureda, Anna
Perez-Callejo, David
Lundberg, Linda
Relf, James
Dixon, Mark
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
Trney, Marek
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24) : 2220 - 2231

← 1 2 3 4 5 →